

Date:

Personal ID number:

• Which treatment did you choose for this patient?

- Cis-Gem ± Avelumab
- Nivo-Cis-Gem + Nivolumab
- Carbo-Gem ± Avelumab (cisplatin-fit patient)
- Carbo-Gem ± Avelumab (cisplatin-unfit patient)
- Pembro-EV
- Immunotherapy monotherapy
- Other: _____

• What were the most important factors influencing your treatment choice? (max 3)

- Expected efficacy
- Side effect/toxicity profile
- Cost
- Patient age
- Performance status
- Comorbidity
- Low tumor burden
- Preference for initial monotherapy (with possible later escalation to combination therapy)
- Patient preference
- Local guidelines
- National treatment recommendations
- Other: _____

• How much did the side effect profile influence your treatment choice?

- Not at all
- Slight
- Moderate
- High
- Very high

• If you chose another first-line regimen, which comorbidities were decisive for not choosing Pembro-EV? (max 3)

- Vascular disease (e.g., myocardial infarction, stroke)
- Diabetes

- Heart failure
- Lung disease (e.g., COPD, fibrosis)
- Polyneuropathy
- Other neurological disease: _____
- Hearing loss
- Chronic kidney disease
- Inflammatory disease: _____
- Skin disease: _____
- Eye disease
- Other: _____
- Comorbidity did not influence my treatment choice

• Which adverse effect risk was most important if you did not choose Pembro-EV?

- Peripheral neuropathy
- Skin toxicity
- Fatigue
- Hyperglycemia
- Other: _____

• Assess the difficulty of choosing between other established first-line treatments and Pembro-EV

- Very easy ■ Quite easy ■ Quite difficult ■ Difficult